Fibrinolytic inhibitor levels and polymorphisms in Behcet disease and their association with thrombosis.

Authors: Ricart, JM  Ramon, LA  Vaya, A  Espana, F  Santaolaria, ML  Todoli, J  Castello, R  Fontcuberta, J  Estelles, A 
Citation: Ricart JM, etal., Br J Haematol. 2008 May;141(5):716-9. doi: 10.1111/j.1365-2141.2008.07078.x. Epub 2008 Mar 12.
Pubmed: (View Article at PubMed) PMID:18341631
DOI: Full-text: DOI:10.1111/j.1365-2141.2008.07078.x

This study aimed to assess the fibrinolytic inhibitors and their association with thrombosis in Behcet disease. Thrombin activatable fibrinolysis inhibitor (TAFI) (P < 0.001) and plasminogen activator inhibitor-1 (PAI-1) levels (P = 0.022) were significantly higher in 79 patients than in 84 controls. No significant differences were observed in CPB2 (TAFI) Thr325Ile and SERPINE1 (PAI1) 4G/5G polymorphism distribution between patients and controls. TAFI activity levels were significantly higher in patients with thrombosis than in those without thrombosis (P = 0.024). In conclusion, the increased TAFI levels in Behcet disease could contribute to the increased risk of thrombosis observed in these patients.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 8547693
Created: 2014-02-19
Species: All species
Last Modified: 2014-02-19
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.